New stock news | BenQ Hospital passed the Hong Kong Stock Exchange hearing as the largest privately-owned for-profit comprehensive hospital group in the East China region.

According to the disclosure from the Hong Kong Stock Exchange on December 9th, Minbase Hospital Group Limited (Minbase Hospital) conducted a listing hearing on the main board of the Hong Kong Stock Exchange, with CICC and Citigroup as joint sponsors. The prospectus shows that Minbase Hospital is a privately owned for-profit comprehensive hospital group in mainland China, currently owning and operating two privately owned for-profit comprehensive hospitals, Nanjing Minbase Hospital and Suzhou Minbase Hospital. According to Frost & Sullivan data, based on total revenue in 2024, the company is the largest privately owned for-profit comprehensive hospital group in East China, with a market share of 1.0% in the region; based on the same criteria, the company ranks seventh among all privately owned for-profit comprehensive hospital groups in the country, with a market share of 0.4% in China; based on bed revenue in 2024, the company ranks first among all privately owned for-profit comprehensive hospital groups in mainland China. As of June 30, 2025, the total construction area of the two hospitals mentioned above is approximately 400,000 square meters, with a total of 1,850 registered beds, and a team of over 1000 experienced doctors, including 35 experts from Taiwan and overseas. In 2024, the company's outpatient visits exceeded 2 million, and the annual inpatient surgeries exceeded 22,000 cases. Nanjing Minbase Hospital started operation in 2008 and was rated as a third class hospital in 2022, the first privately owned hospital in Nanjing, Jiangsu Province to receive a third-class rating. According to Frost & Sullivan data, based on total revenue in 2024, Nanjing Minbase Hospital is the third largest privately owned for-profit comprehensive hospital in China (with a market share of 0.3% in China) and the largest privately owned for-profit comprehensive hospital in Jiangsu Province (with a market share of 2.0% in Jiangsu Province). In addition, Nanjing Minbase Hospital is also one of the first units in China to be certified as a national chest pain center and a national health management demonstration base, with several national and provincial key departments. Suzhou Mingji Hospital started operation in 2013 as a third-class comprehensive hospital. Suzhou Mingji Hospital was certified by the Joint Commission International (JCI) in 2020, and is also a national chest pain center, atrial fibrillation center, and national stroke prevention and treatment center in China. With keen market insight, Suzhou Mingji Hospital adheres to differentiated development and has accumulated unique advantages in departments such as gynecology and pediatrics. In 2023 and 2024, Suzhou Mingji Hospital was designated as a "Jiangsu Province elderly-friendly medical institution" by the Jiangsu Health and Health Commission. According to Frost & Sullivan information, it is also one of the first pilot medical institutions in Suzhou to provide hospice care services. Controlling shareholder Jiah Shida Technology Co., Ltd. was founded in 1984 and listed on the Taiwan Stock Exchange in 1996. It is a global technology group spanning information technology industry, medical services and products (including hospital operation in this group and sales of medical equipment and products), intelligent solutions and network communication business, and its brand effect and advanced technology will continue to bring business synergy opportunities to the company. As the sole entity and brand carrying the medical service business of Jiah Shida Technology Co., Ltd., the company plans to accelerate the expansion of its hospitals and continuously obtain new business growth points by strengthening cooperation with first, second, and community medical institutions to build regional medical consortia. The company believes that the rich experience accumulated in operating two large comprehensive hospitals over the years and the support of the controlling shareholder will continue to support the company's business expansion, enabling the company to successfully integrate newly acquired or newly established medical institutions in different regions and achieve continued growth in a relatively short period of time. Financially, in the fiscal years 2022, 2023, 2024, the years ended 2024 and 2025 as of June 30, Minbase Hospital achieved revenues of approximately RMB 2.336 billion, RMB 2.688 billion, RMB 2.659 billion, RMB 1.33 billion, and RMB 1.312 billion respectively; during the same period, the annual/periodic profits were RMB 89.55 million, approximately RMB 167 million, approximately RMB 109 million, RMB 63.401 million, and RMB 48.704 million respectively.